Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants.
Indomethacin failed to produce permanent ductal closure in any of four premature infants with patent ductus arteriosus to whom the drug was given. Indomethacin half-lives measured in two premature infants were 21 and 24 hours, respectively, much longer than in full-term newborns or adults. Platelet function, as measured by platelet aggregation, was grossly abnormal for two to four days after indomethacin administration, normal values returning only by the ninth and tenth days. Gastrointestinal bleeding and transient renal dysfunction occurred in one infant. Measurement of plasma indomethacin concentrations in sick, low-birthweight infants could help guide indomethacin dose and dosage interval, prevent drug accumulation, and reduce toxicity. Further studies of potential toxicity seem to be indicated before instituting widespread indomethacin administration for ductal closure in premature infants.
D001791:Blood Platelet Disorders / Q000097:blood / Q000139:chemically induced*; D001798:Blood Proteins / Q000378:metabolism; D004374:Ductus Arteriosus, Patent / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006207:Half-Life; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000097:blood / Q000139:chemically induced*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011485:Protein Binding; D013997:Time Factors
D001798:Blood Proteins; D007213:Indomethacin